Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models

Journal of Korean Medical Science

Volumn 24, Issue 5, 2009, Pages 782-788

  Ryu, Se Min ^a   Kim, Hark Jei ^b   Cho, Kyu Ran ^c   Jo, Won Min ^d  

^a Kangwon National University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c College of Medicine   (South Korea)

^d Korea University   (South Korea)

Author keywords

Cardiomyopathies; Myocardial ischemia myocardial reperfusion injury; Receptors endothelin

Indexed keywords

DOXORUBICIN; ENDOTHELIN RECEPTOR; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE; TEZOSENTAN; VASODILATOR AGENT;

ANIMAL; ARTICLE; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; CORONARY BLOOD VESSEL; DISEASE MODEL; DRUG ANTAGONISM; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HYPERTROPHY; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESSURE; RAT; REPERFUSION INJURY; SPRAGUE DAWLEY RAT;

ANIMALS; CARDIOMYOPATHIES; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DOXORUBICIN; HEART FAILURE; HYPERTROPHY; MALE; PRESSURE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; REPERFUSION INJURY; TETRAZOLES; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 75349096044     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.5.782     Document Type: Article

References (35)

1. Parker JD, Thiessen JJ, Reilly R, Tong JH, Stewart DJ, Pandey AS. Human endothelin-1 clearance kinetics revealed by a radiotracer technique. J Pharmacol Exp Ther 1999; 289: 261-5.
2. Inada T, Fujiwara H, Hasegawa K, Araki M, Yamauchi-Kohno R, Yabana H, Fujiwara T, Tanaka M, Sasayama S. Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters. J Am Coll Cardiol 1999; 33: 565-71.
3. Wittner M, Christ GJ, Huang H, Weiss LM, Hatcher VB, Morris SA, Orr GA, Berman JW, Zeballos GA, Douglas SA, Tanowitz HB. Try-panosoma cruzi induces endothelin release from endothelial cells. J Infect Dis 1995; 171: 493-7.
4. Cheng JW. Tezosentan in the management of decompensated heart failure. Cardiol Rev 2005; 13: 28-34.
5. Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VE-RITAS). Am Heart J 2005; 150: 46-53.
6. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993; 14: 385-99.
7. Kaddoura S, Firth JD, Boheler KR, Sugden PH, Poole-Wilson PA. Endothelin-1 is involved in norepinephrine-induced ventricular hyper-trophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 1996; 93: 2068-79.
8. Teerlink JR. The development of new medical treatments for acute decompensated heart failure. Heart Fail Monit 2002; 2: 129-37.
9. Fishman WH, Kaur S, Singh I, Tamirisa P. Endothelin as a therapeutic target in the treatment of cardiovascular disease. In: Frishman WH, Sonnenblick EH, Sica DA, editors, Cardiovascular pharmacotherapeutics. 2nd ed. New York: McGraw-Hill, Medical Pub. Division, 2003; 527-43.
10. Webb DJ. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Endothelin antagonism in heart failure. Circulation 1995; 92: 3372.
11. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr. Increased endothelin in experimental heart failure. Circulation 1990; 82: 2226-30.
12. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
13. Duchman SM, Thohan V, Kalra D, Torre-Amione G. Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure. Curr Opin Cardiol 2000; 15: 136-40.
14. McMurdo L, Thiemermann C, Vane JR. The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. Br J Pharmacol 1994; 112: 75-80.
15. Richard V, Kaeffer N, Hogie M, Tron C, Blanc T, Thuillez C. Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist. Br J Pharmacol 1994; 113: 869-76.
16. Xia Z, Kuo KH, McNeill JH, Ansley DM. Endothelin A and B receptor antagonist bosentan reduces postischemic myocardial injury in the rat: critical timing of administration. Can J Physiol Pharmacol 2005; 83: 259-66.
17. Sakai S, Yorikane R, Miyauchi T, Sakurai T, Kasuya Y, Yamaguchi I, Sugishita Y, Goto K. Altered production of endothelin-1 in the hy-pertrophied rat heart. J Cardiovasc Pharmacol 1995; 26 (Suppl 3): S452-5.
18. Cernacek P, Stewart DJ, Monge JC, Rouleau JL. The endothelin system and its role in acute myocardial infarction. Can J Physiol Pharmacol 2003; 81: 598-606.
19. Nguyen QT, Cernacek P, Calderoni A, Stewart DJ, Picard P, Sirois P, White M, Rouleau JL. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998; 98: 2323-30.
20. Nguyen QT, Cernacek P, Sirois MG, Calderone A, Lapointe N, Stewart DJ, Rouleau JL. Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing. Circulation 2001; 104: 2075-81.
21. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000; 60: 1789-92.
22. Watanabe K, Ohta Y, Kouda T, Sekiguchi T, Sato S, Nakazawa M, Hasegawa G, Naito M, Fuse K, Ito M, Hirono S, Tanabe N, Hanawa H, Kato K, Kodama M, Aizawa Y. Acute effects of endothelin-1 and TAK-044 (ET(A) and ET(B) receptor antagonist) in rats with dilated cardiomyopathy. J Cardiovasc Pharmacol 2000; 36 (Suppl 2): S49-54.
23. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intra-cellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7: 589-600.
24. Houser SR, Margulies KB. Is depressed myocyte contractility centrally involved in heart failure? Circ Res 2003; 92: 350-8.
25. Olson EN. A decade of discoveries in cardiac biology. Nat Med 2004; 10: 467-74.
26. Yorikane R, Sakai S, Miyauchi T, Sakurai T, Sugishita Y, Goto K. Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett 1993; 332: 31-4.
27. Arai M, Yoguchi A, Iso T, Takahashi T, Imai S, Murata K, Suzuki T. Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol 1995; 268: H2084-91.
28. Sirvio ML, Uhlenius N, Stewen P, Metsarinne K, Fyhrquist F. The effect of aortic coarctation on expression of endothelin-1 and endothelin receptors in heart and lungs. Blood Press 1995; 4: 320-3.
29. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC Jr. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580-6.
30. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, Horie H, Ohnishi M, Kinoshita M. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-6.
31. Arnolda L, McGrath B, Cocks M, Sumithran E, Johnston C. Adriamycin cardiomyopathy in the rabbit: an animal model of low out-put cardiac failure with activation of vasoconstrictor mechanisms. Cardiovasc Res 1985; 19: 378-82.
32. Bauch M, Ester A, Kimura B, Victorica BE, Kedar A, Phillips MI. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992; 69: 1492-7.
33. Lako-Futo Z, Szokodi I, Sarman B, Foldes G, Tokola H, Ilves M, Leskinen H, Vuolteenaho O, Skoumal R, deChatel R, Ruskoaho H, Toth M. Evidence for a functional role of angiotensin II type 2 receptor in the cardiac hypertrophic process in vivo in the rat heart. Circulation 2003; 108: 2414-22.
34. Gomez-Garre D, Guerra M, Gonzalez E, Lopez-Farre A, Riesco A, Caramelo C, Escanero J, Egido J. Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet-activating factor. Eur J Pharmacol 1992; 224: 167-72.
35. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995; 91: 1872-85.